Pα+ Psychedelic Bulletin #207: Lykos Rebrands to Resilient; Pharma Pushes Back on Norway’s Ketamine Reimbursement Decision; AbbVie-Gilgamesh Deal Viewed as Validation Post published:August 28, 2025 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #206: Q2’25 Psychedelic Lobbying; Tabernanthalog’s Neuroplasticity Pathway; UK Moves to Ease Schedule I Research Restrictions Post published:August 8, 2025 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling? Post published:August 1, 2025 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research Post published:July 25, 2025 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch? Post published:July 14, 2025 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber; Judge Recommends Schedule I Placement for DOI and DOC Post published:June 27, 2025 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes Leader in Ibogaine Research as Governor Signs $50M Match-Funding Bill; High-Dose LSD Shows Potential in Depression, But Findings Are Fragile Post published:June 13, 2025 Post category:Psychedelic Bulletin/Pα+
Psychedelic Bulletin #200: Can Czechia Deliver on Psilocybin Access? A Closer Look at ‘atai Beckley’; Q1’25 Psychedelic Lobbying Update; Catching Up with the Class of Bulletin #100 Post published:June 6, 2025 Post category:Psychedelic Bulletin
Pα+ Psychedelic Bulletin #199: Lykos Takeover Nears Completion; Fewer than 100 Patients Received Psychedelics in Australia During First 18 Months of Access; Ibogaine Bill Clears Texas Legislature Amid THC Crackdown Post published:May 30, 2025 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for Beckley Post published:May 23, 2025 Post category:Psychedelic Bulletin/Pα+